Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.
OBJECTIVE
To evaluate the safety and efficacy of tirofiban in high risk patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) after percutaneous coronary intervention (PCI).


METHODS
A total of 240 patients were randomized to either a tirofiban group or a control group.


RESULTS
Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events (MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1).


CONCLUSIONS
The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.
Yan
Zhenxian
Z
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Zhou
Yujie
Y
Zhao
Yingxin
Y
Li
Yueping
Y
Nie
Xiaomin
X
Zhou
Zhiming
Z
Jia
Dean
D
D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006331:Heart Diseases / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D018570:Risk Assessment; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D000077466:Tirofiban; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D019210:Troponin I; D014443:Tyrosine; D052279:Creatine Kinase, MB Form; D000077466:Tirofiban